Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 78Carcinoma, Non-Small-Cell Lung 43Nasopharyngeal Carcinoma 24Lung Neoplasms 23Breast Neoplasms 14Cholangiocarcinoma 13Lymphoma, Large B-Cell, Diffuse 12Neoplasm Metastasis 11Ovarian Neoplasms 10Lymphoma, Extranodal NK-T-Cell 10Recurrence 9Biliary Tract Neoplasms 9Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Nasopharyngeal Neoplasms 6Lymphoma 6Lymphoma, T-Cell, Peripheral 5Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rectal Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Gallbladder Neoplasms 4Colonic Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma of Lung 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell 3

Interventions

irinotecan sucrosofate 1Taxes 1Radiosurgery 1Oxaliplatin 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Cancer Non-resectable × Gemcitabine × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡